S&P 500   4,288.39 (+0.01%)
DOW   33,433.35 (-0.22%)
QQQ   361.26 (+0.83%)
AAPL   173.75 (+1.48%)
MSFT   321.80 (+1.92%)
META   306.82 (+2.20%)
GOOGL   134.17 (+2.53%)
AMZN   129.46 (+1.84%)
TSLA   251.60 (+0.55%)
NVDA   447.82 (+2.95%)
NIO   8.79 (-2.77%)
BABA   86.53 (-0.24%)
AMD   103.27 (+0.44%)
T   14.67 (-2.33%)
F   12.31 (-0.97%)
MU   67.96 (-0.10%)
CGC   0.74 (-6.35%)
GE   108.79 (-1.59%)
DIS   81.67 (+0.76%)
AMC   8.16 (+2.00%)
PFE   33.94 (+2.32%)
PYPL   58.56 (+0.17%)
NFLX   380.33 (+0.72%)
S&P 500   4,288.39 (+0.01%)
DOW   33,433.35 (-0.22%)
QQQ   361.26 (+0.83%)
AAPL   173.75 (+1.48%)
MSFT   321.80 (+1.92%)
META   306.82 (+2.20%)
GOOGL   134.17 (+2.53%)
AMZN   129.46 (+1.84%)
TSLA   251.60 (+0.55%)
NVDA   447.82 (+2.95%)
NIO   8.79 (-2.77%)
BABA   86.53 (-0.24%)
AMD   103.27 (+0.44%)
T   14.67 (-2.33%)
F   12.31 (-0.97%)
MU   67.96 (-0.10%)
CGC   0.74 (-6.35%)
GE   108.79 (-1.59%)
DIS   81.67 (+0.76%)
AMC   8.16 (+2.00%)
PFE   33.94 (+2.32%)
PYPL   58.56 (+0.17%)
NFLX   380.33 (+0.72%)
S&P 500   4,288.39 (+0.01%)
DOW   33,433.35 (-0.22%)
QQQ   361.26 (+0.83%)
AAPL   173.75 (+1.48%)
MSFT   321.80 (+1.92%)
META   306.82 (+2.20%)
GOOGL   134.17 (+2.53%)
AMZN   129.46 (+1.84%)
TSLA   251.60 (+0.55%)
NVDA   447.82 (+2.95%)
NIO   8.79 (-2.77%)
BABA   86.53 (-0.24%)
AMD   103.27 (+0.44%)
T   14.67 (-2.33%)
F   12.31 (-0.97%)
MU   67.96 (-0.10%)
CGC   0.74 (-6.35%)
GE   108.79 (-1.59%)
DIS   81.67 (+0.76%)
AMC   8.16 (+2.00%)
PFE   33.94 (+2.32%)
PYPL   58.56 (+0.17%)
NFLX   380.33 (+0.72%)
S&P 500   4,288.39 (+0.01%)
DOW   33,433.35 (-0.22%)
QQQ   361.26 (+0.83%)
AAPL   173.75 (+1.48%)
MSFT   321.80 (+1.92%)
META   306.82 (+2.20%)
GOOGL   134.17 (+2.53%)
AMZN   129.46 (+1.84%)
TSLA   251.60 (+0.55%)
NVDA   447.82 (+2.95%)
NIO   8.79 (-2.77%)
BABA   86.53 (-0.24%)
AMD   103.27 (+0.44%)
T   14.67 (-2.33%)
F   12.31 (-0.97%)
MU   67.96 (-0.10%)
CGC   0.74 (-6.35%)
GE   108.79 (-1.59%)
DIS   81.67 (+0.76%)
AMC   8.16 (+2.00%)
PFE   33.94 (+2.32%)
PYPL   58.56 (+0.17%)
NFLX   380.33 (+0.72%)

MaxCyte (MXCT) Stock Forecast, Price & News

$3.02
-0.10 (-3.21%)
(As of 10/2/2023 ET)
Compare
Today's Range
$3.01
$3.15
50-Day Range
$3.02
$4.78
52-Week Range
$2.99
$7.50
Volume
385,497 shs
Average Volume
495,171 shs
Market Capitalization
$312.69 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.50

MaxCyte MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
247.7% Upside
$10.50 Price Target
Short Interest
Bearish
2.30% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$120,981 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.37) to ($0.38) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.03 out of 5 stars

Medical Sector

600th out of 969 stocks

Commercial Physical Research Industry

11th out of 14 stocks


MXCT stock logo

About MaxCyte (NASDAQ:MXCT) Stock

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.

MXCT Price History

MXCT Stock News Headlines

Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
PRTS, CRBU and NDLS are among after hour movers
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
Recap: MaxCyte Q1 Earnings
MaxCyte Is Poised For A Strong Rebound
MaxCyte, Curamys In Strategic Platform License Deal
MaxCyte, Inc. (NASDAQ: MXCT)
See More Headlines
Receive MXCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MaxCyte and its competitors with MarketBeat's FREE daily newsletter.

MXCT Company Calendar

Last Earnings
8/09/2023
Today
10/02/2023
Next Earnings (Estimated)
11/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Commercial physical research
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MXCT
Employees
125
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.50
High Stock Price Forecast
$12.00
Low Stock Price Forecast
$9.00
Forecasted Upside/Downside
+236.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-23,570,000.00
Pretax Margin
-80.22%

Debt

Sales & Book Value

Annual Sales
$44.26 million
Book Value
$2.47 per share

Miscellaneous

Free Float
97,325,000
Market Cap
$323.04 million
Optionable
Optionable
Beta
0.84
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Mr. Douglas Arthur Doerfler (Age 67)
    Founder, Pres, CEO & Exec. Director
    Comp: $1.2M
  • Dr. Cenk Sumen Ph.D. (Age 49)
    Chief Scientific Officer
    Comp: $575.6k
  • Mr. Maher Masoud (Age 48)
    Exec. VP, Gen. Counsel & Sec.
    Comp: $612.07k
  • Mr. Douglas J. Swirsky CFA (Age 54)
    CPA, Chief Financial Officer
  • Mr. Ronald Evan Holtz CPA (Age 65)
    Ph.D., Exec. VP of Admin.
  • Mr. Sean Menarguez
    Director of Investor Relations
  • Mr. Thomas Michael Ross (Age 62)
    Exec. VP of Global Sales & Marketing
  • Dr. J. Stark Thompson Ph.D. (Age 81)
    Consultant
  • Dr. James Brady Ph.D.
    Sr. VP of Technical Applications & Customer Support
  • Dr. Sarah Haecker Meeks Ph.D.
    Sr. VP of Bus. Devel.













MXCT Stock - Frequently Asked Questions

Should I buy or sell MaxCyte stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MaxCyte in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MXCT shares.
View MXCT analyst ratings
or view top-rated stocks.

What is MaxCyte's stock price forecast for 2023?

1 analysts have issued 1 year target prices for MaxCyte's stock. Their MXCT share price forecasts range from $9.00 to $12.00. On average, they expect the company's stock price to reach $10.50 in the next twelve months. This suggests a possible upside of 236.5% from the stock's current price.
View analysts price targets for MXCT
or view top-rated stocks among Wall Street analysts.

How have MXCT shares performed in 2023?

MaxCyte's stock was trading at $5.46 at the beginning of 2023. Since then, MXCT shares have decreased by 42.9% and is now trading at $3.12.
View the best growth stocks for 2023 here
.

When is MaxCyte's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our MXCT earnings forecast
.

How were MaxCyte's earnings last quarter?

MaxCyte, Inc. (NASDAQ:MXCT) issued its quarterly earnings results on Wednesday, August, 9th. The company reported ($0.10) EPS for the quarter, hitting the consensus estimate of ($0.10). The firm earned $9.04 million during the quarter, compared to analyst estimates of $11 million. MaxCyte had a negative trailing twelve-month return on equity of 13.09% and a negative net margin of 80.22%.

When did MaxCyte IPO?

(MXCT) raised $150 million in an IPO on Friday, July 30th 2021. The company issued 12,000,000 shares at a price of $11.50-$13.50 per share.

What is MaxCyte's stock symbol?

MaxCyte trades on the NASDAQ under the ticker symbol "MXCT."

How do I buy shares of MaxCyte?

Shares of MXCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MaxCyte's stock price today?

One share of MXCT stock can currently be purchased for approximately $3.12.

How much money does MaxCyte make?

MaxCyte (NASDAQ:MXCT) has a market capitalization of $323.04 million and generates $44.26 million in revenue each year. The company earns $-23,570,000.00 in net income (profit) each year or ($0.32) on an earnings per share basis.

How many employees does MaxCyte have?

The company employs 125 workers across the globe.

How can I contact MaxCyte?

MaxCyte's mailing address is 22 FIRSTFIELD ROAD SUITE 110, GAITHERSBURG MD, 20878. The official website for the company is maxcyte.com. The company can be reached via phone at 301-944-1700, via email at ir@maxcyte.com, or via fax at 301-944-1703.

This page (NASDAQ:MXCT) was last updated on 10/2/2023 by MarketBeat.com Staff

My Account -